Forbes features an interview with Deborah Derrick, president of Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, in which she “discusse[s] her motivations for pursuing a career in international affairs and social change, her experience as a senior program officer at the [Bill & Melinda Gates Foundation], what lessons she learned during her time at Gates that are most applicable in her new executive role at Friends of the Global Fight, the current landscape of challenges and solutions, and the role of technology in accelerating progress.” In the interview, Derrick said, “The mobilization to defeat these diseases in the past decade has been stunningly successful. … But there is so much more that needs to be done. If we don’t muster the resources to keep up the fight, and all commit to doing our part in a time of constrained resources, we risk backsliding on the progress we’ve already invested in” (Kanani, 9/21).
The U.S. Army news service reports on a five-day Medical Civil Action Program, or MEDCAP, in Tanzania, during which “Tanzanian medical providers working in partnership with U.S. service members from Combined Joint Task Force-Horn of Africa provided medical care to more than 2,100 Tanzanian women and children.” According to the news service, “The program supported the Tanzanian Health Initiative, a program that seeks to provide a comprehensive approach to health for the Tanzanian people and parallels the U.S. government’s Global Health Initiative.”
TIME reports on evidence along the Thai-Cambodia border that the malaria parasite is gaining resistance to artemisinin â€“ “the only remaining effective drug in the world’s arsenal against malaria’s most deadly strain.”
“Two years after some $22 million in donor funds were pumped into malaria control along the Cambodia-Thailand border to fight off suspected resistance to treatment, health workers say the battle is not over,” IRIN reports, adding, “The government reported 103,000 malaria infections and 151 deaths nationwide in 2010. A year later, 85,000 reported infections led to 93 deaths — a 38-percent decline in mortality.” “‘If you take your foot off the â€¦ [accelerator] we can lose everything we have done in the past two to three years,’ Steven Bjorge, anti-malaria team leader in Cambodia for the [WHO], told IRIN in February 2012,” the news service writes.
A BBC News article and related video examine the eastern Democratic Republic of Congo’s battle with malaria. “‘Malaria is the main killer here in Congo, especially for pregnant women and children,’ says Dr. Vincker Lushombo, from Save the Children,” BBC writes. “Two decades of conflict and chaos have destroyed key infrastructure and left many families in the east living in makeshift camps, often exposed to malarial swamps,” according to the news service.
“Over the next few weeks, appropriators will be engaged in the challenging task of evaluating U.S. foreign assistance funding, including how effectively Congress’ global health investments are being used,” Charles Lyons, president and CEO of the Elizabeth Glaser Pediatric AIDS Foundation; Molly Joel Coye, interim president and CEO of PATH; Carolyn Miles, president and CEO of Save the Children; and Richard Stearns, president of World Vision, write in this Roll Call opinion piece. They continue, “As organizations funded in part by the U.S. government to implement global health programs in the field,” we “see firsthand how U.S. global health programs are working, and why now is not the time to cut multilateral and bilateral funding for these efforts.”
The Globe and Mail reports on “a massive resurgence of malaria [in the Democratic Republic of the Congo] that has baffled scientists and raised doubts about the global fight against the deadly scourge.” “Malaria is already the single biggest killer in Congo, with nearly 200,000 people dying annually, and now the trend is worsening,” the newspaper writes, noting that “the number of malaria patients has soared by a stunning 250 percent … since 2009,” according to data from Medecins Sans Frontieres (MSF).
In this post in the Guardian’s “The Observer,” Mark Honigsbaum, a research associate at the University of Zurich’s Institute for Medical History, interviews Peter Seeberger, the director of the Max Planck Institute of Colloids and Interfaces in Potsdam, Germany, about a recent announcement that Seeberger and colleague FranÃ§ois LÃ©vesque “have discovered a simple and cost-effective way of synthesizing artemisinin from the waste products of the” sweet wormwood plant from which it is extracted. Honigsbaum notes that “extracting artemisinin is expensive and because it takes time to cultivate the plant there are often bottlenecks in supply,” and writes, “Their discovery has the potential to make the drug more affordable for the 225 million people affected by malaria every year” (2/4).
In this post in her Global Health Blog, Guardian Health Editor Sarah Boseley examines the potential impact of reform within the Global Fund to Fight AIDS, Tuberculosis and Malaria on the organization’s future. She writes, “It’s been only seven weeks since banker Gabriel Jaramillo took over as general manager of the [fund], but it is already clear the worthy organization set up by Kofi Annan to channel money to treat and prevent diseases in poor countries is a leaner, meaner machine.” She continues, “Jaramillo, former chair and chief executive of Sovereign Bank, brings a tougher attitude to the organization.”
“The World Health Organization heralded major gains Tuesday in the fight against malaria, one of the developing world’s biggest killers, but warned universal access to treatment remains elusive,” Agence France-Presse reports, noting, “The assessment came on the eve of World Malaria Day,” observed Wednesday and “designed to shine the light on the mosquito-borne parasite that killed 655,000 people in 2010, including 560,000 children under five” (4/24). “A massive acceleration in the global distribution of mosquito nets, the expansion of programs to spray the insides of buildings with insecticides, and an increase in access to prompt antimalarial treatment has brought down malaria mortality rates by more than a quarter worldwide, and by one-third in Africa since 2000,” but “simply maintaining current rates of progress will not be enough to meet global targets for malaria control,” the agency writes in a news release (4/24).